http://orcid.org/0000-0002-0643-4008
Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Po-Ku Chen, Shiow-Jiuan Wey & Der-Yuan Chen. (2022) Interleukin-18: a biomarker with therapeutic potential in adult-onset Still’s disease. Expert Review of Clinical Immunology 18:8, pages 823-833.
Read now
Read now
Giulio Cavalli, Nicola Farina, Corrado Campochiaro, Elena Baldissera & Lorenzo Dagna. (2020) Current treatment options and safety considerations when treating adult-onset Still’s disease. Expert Opinion on Drug Safety 19:12, pages 1549-1558.
Read now
Read now
Piero Ruscitti, Alessandro Conforti, Viktoriya Pavlych & Roberto Giacomelli. (2019) Inhibiting inflammatory cytokines in adult onset Still’s disease. Current trends and new therapeutic perspectives. Expert Opinion on Orphan Drugs 7:12, pages 547-554.
Read now
Read now
Dae Hyun Yoo. (2019) Biologics for the treatment of adult-onset still’s disease. Expert Opinion on Biological Therapy 19:11, pages 1173-1190.
Read now
Read now
Santos Castañeda, Dolores Martínez-Quintanilla, José L. Martín-Varillas, Noelia García-Castañeda, Belén Atienza-Mateo & Miguel A. González-Gay. (2019) Tocilizumab for the treatment of adult-onset Still’s disease. Expert Opinion on Biological Therapy 19:4, pages 273-286.
Read now
Read now
Santos Castañeda, Belén Atienza-Mateo, José L. Martín-Varillas, José M. Serra López-Matencio & Miguel A. González-Gay. (2018) Anakinra for the treatment of adult-onset Still’s disease. Expert Review of Clinical Immunology 14:12, pages 979-992.
Read now
Read now
Piero Ruscitti & Roberto Giacomelli. (2018) Pathogenesis of adult onset still’s disease: current understanding and new insights. Expert Review of Clinical Immunology 14:11, pages 965-976.
Read now
Read now
Piero Ruscitti, Francesco Ursini, Paola Cipriani, Giovambattista De Sarro & Roberto Giacomelli. (2017) Biologic drugs in adult onset Still’s disease: a systematic review and meta-analysis of observational studies. Expert Review of Clinical Immunology 13:11, pages 1089-1097.
Read now
Read now
Articles from other publishers (22)
Mengyuan Duan, Min Shen, Yongting Zhou, Yi He, Zehao Guo, Caiying Ye, Juan Li & Lei Zhu. (2022) AIM2 and NLRC4-driven inflammasome activation in adult-onset Still’s disease and the preliminary therapeutic effect exploration of carboxyamidotriazole. Clinical Rheumatology 42:6, pages 1635-1643.
Crossref
Crossref
Chihiro Imaizumi, Masaya Saito, Fumito Abe, Hajime Kaga, Ayano Saito, Mizuho Nara, Saeko Kameyama, Hiroshi Miura, Hitoshi Ogasawara, Takeo Hirakawa, Makito Mizunuma, Makiko Satoh, Atsushi Komatsuda, Yukihiro Terada & Naoto Takahashi. (2022) Adult-onset Still's Disease during Pregnancy Treated with Tocilizumab. Internal Medicine 61:20, pages 3137-3140.
Crossref
Crossref
Kuo-Tung Tang, Chia-Wei Hsieh, Hsin-Hua Chen, Yi-Ming Chen, Shih-Hsin Chang, Po-Hao Huang, Joung-Liang Lan & Der-Yuan Chen. (2021) The effectiveness of tocilizumab in treating refractory adult-onset Still’s disease with dichotomous phenotypes: IL-18 is a potential predictor of therapeutic response. Clinical Rheumatology 41:2, pages 557-566.
Crossref
Crossref
Petros Efthimiou, Olga Petryna, Priscila Nakasato & Apostolos Kontzias. (2022) New insights on multigenic autoinflammatory diseases. Therapeutic Advances in Musculoskeletal Disease 14, pages 1759720X2211178.
Crossref
Crossref
Cristina Segú-Vergés, Mireia Coma, Christoph Kessel, Serge Smeets, Dirk Foell & Anna Aldea. (2021) Application of systems biology-based in silico tools to optimize treatment strategy identification in Still’s disease. Arthritis Research & Therapy 23:1.
Crossref
Crossref
Nikolaos Marketos, Amalia Patelli, Nektaria Papadopoulou-Marketou & Dimitrios Ioakeimidis. (2021) Anakinra for Adult-Onset Still’s Disease Despite Old Age. JCR: Journal of Clinical Rheumatology 27:8S, pages S732-S734.
Crossref
Crossref
Petros Efthimiou, Apostolos Kontzias, Peter Hur, Kavita Rodha, G S Ramakrishna & Priscila Nakasato. (2021) Adult-onset Still's disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies. Seminars in Arthritis and Rheumatism 51:4, pages 858-874.
Crossref
Crossref
Po-Ku Chen & Der-Yuan Chen. (2021) An Update on the Pathogenic Role of Macrophages in Adult-Onset Still’s Disease and Its Implication in Clinical Manifestations and Novel Therapeutics. Journal of Immunology Research 2021, pages 1-11.
Crossref
Crossref
Zhong-Bin Han, Ju Wu, Jing Liu, He-Ming Li, Kai Guo & Tong Sun. (2021) Adult-onset Still's disease evolving with multiple organ failure and death: A case report and review of the literature. World Journal of Clinical Cases 9:4, pages 886-897.
Crossref
Crossref
Corrado Campochiaro, Nicola Farina, Alessandro Tomelleri, Giacomo De Luca, Elena Baldissera, Giulio Cavalli & Lorenzo Dagna. (2021) Drug retention rates of biological agents in adult onset Still's disease. Seminars in Arthritis and Rheumatism 51:1, pages 1-6.
Crossref
Crossref
Mirna Reihl Crnogaj, Darija Čubelić, Antonija Babić, Miroslav Mayer & Branimir Anić. (2020) Treatment of refractory adult onset Still’s disease with tocilizumab—a single centre experience and literature review. Rheumatology International 40:8, pages 1317-1325.
Crossref
Crossref
Franco Pandolfi, Laura Franza, Valentina Carusi, Simona Altamura, Gloria Andriollo & Eleonora Nucera. (2020) Interleukin-6 in Rheumatoid Arthritis. International Journal of Molecular Sciences 21:15, pages 5238.
Crossref
Crossref
Fabio Marazzi, Valeria Masiello, Gianluca Franceschini, Silvia Bosello, Francesca Moschella, Daniela Smaniotto, Stefano Luzi, Antonino Mulé, Maria Antonietta Gambacorta, Elisa Gremese, Riccardo Masetti & Vincenzo Valentini. (2020) Adult Onset Still's Disease and Radiotherapy treatment for breast cancer: Case report about management of this rare association and literature review. Reports of Practical Oncology & Radiotherapy 25:4, pages 527-532.
Crossref
Crossref
Elizabeth Lorenzo-Hernández, Fernando Salgado-Ordóñez, Iván Pérez-de-Pedro, Gloria Millán-García & Ricardo Gómez-Huelgas. (2020) Un síndrome febril de larga duración. Revista Española de Casos Clínicos en Medicina Interna 5:1, pages 27-30.
Crossref
Crossref
Meng-Yan Wang, Jin-Chao Jia, Cheng-De Yang & Qiong-Yi Hu. (2019) Pathogenesis, disease course, and prognosis of adult-onset Still's disease: an update and review. Chinese Medical Journal 132:23, pages 2856-2864.
Crossref
Crossref
Yuko Kaneko, Hideto Kameda, Kei Ikeda, Tomonori Ishii, Kosaku Murakami, Hyota Takamatsu, Yoshiya Tanaka, Takayuki Abe & Tsutomu Takeuchi. (2019) Response to: ‘Tocilizumab in patients with adult-onset Still’s disease refractory to glucocorticoid treatment’ by Lee. Annals of the Rheumatic Diseases 78:12, pages e134-e134.
Crossref
Crossref
Young Ho Lee. (2019) Tocilizumab in patients with adult-onset Still’s disease refractory to glucocorticoid treatment. Annals of the Rheumatic Diseases 78:12, pages e133-e133.
Crossref
Crossref
Piero Ruscitti, Paola Cipriani, Vasiliki Liakouli, Giuliana Guggino, Francesco Carubbi, Onorina Berardicurti, Francesco Ciccia & Roberto Giacomelli. (2019) Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study. Medicine 98:15, pages e15123.
Crossref
Crossref
Wei Li, Peng Dong, Fang Liu, Yang Jiang, Yuanzheng Li & Banghe Li. (2019) Intermittent High-Spiking Fever, Muscle and Joint Pain with Sudden Chest Pain: Adult-Onset Still's Disease?. Cardiology Plus 4:1, pages 35-38.
Crossref
Crossref
W. Winn Chatham. 2019. Cytokine Storm Syndrome. Cytokine Storm Syndrome
423
434
.
Dae Hyun Yoo. (2017) Utility and drawbacks of [18]F-fluorodeoxyglucose positron emission tomography in the evaluation of adult-onset Still’s disease. The Korean Journal of Internal Medicine 32:6, pages 998-1001.
Crossref
Crossref
J.P. LimaJr.Jr., J.P.S. Andrade, J.M.C.A. Garcia, A.L.M. Villela & G.S. Campos. (2017) DOENÇA DE STILL DO ADULTO GRAVE COM REMISSÃO APÓS TOCILIZUMABE: RELATO DE CASO. Revista Brasileira de Reumatologia 57, pages S290.
Crossref
Crossref